3 recruiting, 1 active not recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Interstitial Lung Diseases: new trials by email Literature Review of Interstitial Lung Diseases trials Research Report on Interstitial Lung Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression Nerandomilast, Placebo matching nerandomilast - Interstitial Lung Diseases | Phase 3 | Recruiting | Boehringer Ingelheim | 466 | 2026-09-17 | 2026-10-28 |
| A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis Nerandomilast, Placebo - Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities | Phase 3 | Recruiting | Boehringer Ingelheim | 80 | 2026-02-10 | 2026-10-28 |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases Nerandomilast, Placebo matching nerandomilast - Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases | Phase 3 | Active not recruiting | Boehringer Ingelheim | 414 | 2025-09-13 | 2026-10-28 |
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis CABA-201 - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Recruiting | Cabaletta Bio | 37 | 2024-07-02 | 2026-10-16 |
Lung Diseases, Interstitial (4) · Autoimmune Diseases (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1)
Lung Diseases (4) · Respiratory Tract Diseases (4) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
BI 1015550 (1)
Boehringer Ingelheim (3) · Cabaletta Bio (1)
United States (4) · Australia (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Netherlands (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Argentina (2) · Austria (2) · Belgium (2) · Canada (2) · China (2)
2025 (1)